^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Merkel Cell Carcinoma |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Excerpt:
...To address whether immune infiltrates and PD-L1 expression are associated with survival.`...
Trial ID:
Source:
Title:
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Published date:
05/08/2020
Excerpt:
Median OS in patients with PD-L1+ (n=57) or PD-L1− (n=16) tumors was 12.9 months (95% CI 8.7 to 29.6 months) and 7.3 months (95% CI 3.4 to 14.0 months), respectively...
DOI:
10.1136/jitc-2020-000674
